Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.

By K. Sjoquist, Fracp, R. Simes, Gebski Mstat, Alexandra Hospital, A. Brisbane, Peter Brisbane, C. Maccallum, Centre, V. Gebski and 5 more. The Lancet Oncology, 2011

1,613 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Surgery

View Paper: https://www.semanticscholar.org/paper/b2d9c17666c9a68259bfdaf0acf3789ad2d9c02e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Han Yang
2. Hui Liu
3. Florian Lordick
4. Yu-ping Chen
5. Chengchu Zhu
6. W. Fang
7. Zhentao Yu
8. X. D’Journo

Citations in the corpus

• Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “Meta-analyses showed a small but significant benefit for preoperative chemotherapy [12, 13], but they included very limited numbers of patients with localised tumours (e.”
• Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial (2018, background): “Recent evidence has suggested a survival benefit from neoadjuvant concurrent chemoradiotherapy followed by surgery.(4) However, the results from randomized controlled trials comparing neoadjuvant chemoradiotherapy (NCRT) followed by surgery with surgery alone have been Author affiliations and suppor”